References
- Sloan E. P., Koenigsberg M., Gens D., Cipolle M., Runge J., Malloy M. N., Rodman G., Jr. Diaspirin crosslinked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 1999; 282: 1857–1864
- Przyberski R. J., Daily E. K., Birnbaum M. L. The pressor effect of hemoglobin -good or bad?. “Advances in blood substitutes: industrial opportunities and medical challenges, Winslow, Vandegriff, Intaglietta. Birkhauser, Boston 1997; Chapter 5: 71–90
- Intaglietta M. Microcirculatory basis for the design of artificial blood. Microcirculation 1999; 6: 247–258
- “Blood substitutes: present and future perspective”, E. Tsuchida. Elsevier, Amsterdam 1998
- “Blood substitutes: Principles, Methods, Products and Clinical Trials”, T. M.S. Chang. Karger, Basel 1997
- “Red blood cell substitutes: basic principles and clinical applications”, A. S. Rudolph, R. Rabinovici, G. Z. Feuerstein. Marcel Dekker, New York 1998
- Spahn D. R., van Brempt R., Theilmeier G., Reibold J., Welte M., Heinzerling H., Brick K. M., Keipert P. E., Messmer K. Perflubron emulsion delays blood transfusion in othopedic surgery. Anesthesiology 1999; 91: 1195–1208
- Holmberg J. A. Potential use of red blood substitutes within the military. “Red blood cell substitutes: basic principle and clinical applications”, Rudolph, Rabinovici, Feuerstein. Marcel Dekker, New York 1998; 17–27
- Sekiguchi S. Blood substitute research of the national health and welfare science. Artif. Blood 1996; 4: 85–89
- Winslow R. M. The role of blood substitutes in emerging healthcare systems. “Blood substitutes: present and future perspective”, Tsuchida. Elsevier, Amsterdam 1998; 15–32